YZY Biopharma closes $30M Series Pre-C to support bispecific antibodies and COVID vaccine; Zhiyi Biotech, HEP Pharma
Elise Mak ·07/04/2022

Top news story of the day:

YZY Biopharma closes $30M Series Pre-C to support bispecific antibodies and COVID vaccine

YZY Biopharma, of Wuhan, raised RMB200 million ($30 million) in Series Pre-C round to advance its bispecific antibodies and COVID vaccine candidates.

The financing round was supported by Wuhan Hi-tech, Hubei Science Technology Investment Group and Optics Valley.

Its core program is M701, the first EpCAM/CD3-targeted antibody candidate to enter clinical trials. It is now being tested in phase II trials for the treatment of malignant ascites/pleural effusion in EpCAM-positive tumors.

Another key program is Y2019, a recombinant SARS-CoV-2 vaccine that the company said could induce neutralizing antibodies against Beta, Delta and Omicron variants. YZY Biopharma said the vaccine can be stored above 4°C, making it a stable candidate for rapid mass production. It is set to enter phase II trials soon.

By Elise Mak

What else in China:

Zhiyi Biotech has closed a ¥100 million ($15 million) Series B++ round of funding, which will be used to accelerate the clinical advancement of its self-developed LBP drugs.

HEP Pharma has completed a pre-B round of financing of tens of millions of RMB, which will be used to advance the clinical development of hepalatide, its new hepatitis B/D drug.

By Sarina Yang

Keywords: YZY Biopharma Zhiyi Biotech HEP Pharma
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement